MX2020011955A - Derivados heterociclicos y uso de los mismos. - Google Patents
Derivados heterociclicos y uso de los mismos.Info
- Publication number
- MX2020011955A MX2020011955A MX2020011955A MX2020011955A MX2020011955A MX 2020011955 A MX2020011955 A MX 2020011955A MX 2020011955 A MX2020011955 A MX 2020011955A MX 2020011955 A MX2020011955 A MX 2020011955A MX 2020011955 A MX2020011955 A MX 2020011955A
- Authority
- MX
- Mexico
- Prior art keywords
- pain
- disease
- nasal
- inflammatory
- treatment
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 208000003251 Pruritus Diseases 0.000 abstract 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009137 Chronic sinusitis Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 208000027601 Inner ear disease Diseases 0.000 abstract 1
- 208000000592 Nasal Polyps Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060932 Postoperative adhesion Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 abstract 1
- 208000024376 chronic urticaria Diseases 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010023332 keratitis Diseases 0.000 abstract 1
- 201000010666 keratoconjunctivitis Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000003349 osteoarthritic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 208000027491 vestibular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180062254 | 2018-05-31 | ||
| PCT/KR2019/006553 WO2019231270A1 (en) | 2018-05-31 | 2019-05-31 | Heterocyclic derivatives and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011955A true MX2020011955A (es) | 2021-01-15 |
Family
ID=68698381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011955A MX2020011955A (es) | 2018-05-31 | 2019-05-31 | Derivados heterociclicos y uso de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210198259A1 (https=) |
| EP (1) | EP3807282A4 (https=) |
| JP (1) | JP2021525738A (https=) |
| KR (1) | KR102344295B1 (https=) |
| CN (1) | CN112204032A (https=) |
| AU (1) | AU2019279421A1 (https=) |
| BR (1) | BR112020023946A2 (https=) |
| CA (1) | CA3098825A1 (https=) |
| MX (1) | MX2020011955A (https=) |
| SG (1) | SG11202010985TA (https=) |
| TW (1) | TW202021969A (https=) |
| WO (1) | WO2019231270A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| IL298760A (en) | 2020-06-05 | 2023-02-01 | Kinnate Biopharma Inc | Fibroblast growth factor receptor kinase inhibitors |
| EP4067357A1 (en) * | 2021-03-30 | 2022-10-05 | JW Pharmaceutical Corporation | Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate |
| CN113929634A (zh) * | 2021-11-22 | 2022-01-14 | 山西永津集团有限公司 | 一种2,3-二溴喹喔啉的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE358395B (https=) * | 1967-09-27 | 1973-07-30 | Siegfried Ag | |
| BRPI0407926A (pt) * | 2003-03-27 | 2006-02-21 | Pfizer Prod Inc | 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas |
| TW201024297A (en) * | 2008-09-10 | 2010-07-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| TW201204727A (en) * | 2010-03-10 | 2012-02-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| TW201206936A (en) * | 2010-07-19 | 2012-02-16 | Alcon Res Ltd | Methods and compositions for the treatment of allergy |
| TWI551600B (zh) * | 2011-09-30 | 2016-10-01 | Ｃ＆Ｃ新藥研究所 | 新穎雜環衍生物及其用途 |
| CA2904364A1 (en) * | 2013-03-15 | 2014-09-25 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
| JP2018537450A (ja) * | 2015-11-16 | 2018-12-20 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ | Ｄｎａメチルトランスフェラーゼ阻害剤としての新規化合物 |
| JP7212612B2 (ja) * | 2016-07-28 | 2023-01-25 | プロメガ コーポレイション | セレンテラジン類縁体 |
-
2019
- 2019-05-30 TW TW108118749A patent/TW202021969A/zh unknown
- 2019-05-31 JP JP2020566706A patent/JP2021525738A/ja not_active Withdrawn
- 2019-05-31 US US17/057,753 patent/US20210198259A1/en not_active Abandoned
- 2019-05-31 AU AU2019279421A patent/AU2019279421A1/en not_active Abandoned
- 2019-05-31 CA CA3098825A patent/CA3098825A1/en active Pending
- 2019-05-31 MX MX2020011955A patent/MX2020011955A/es unknown
- 2019-05-31 SG SG11202010985TA patent/SG11202010985TA/en unknown
- 2019-05-31 EP EP19810281.6A patent/EP3807282A4/en not_active Withdrawn
- 2019-05-31 CN CN201980035540.4A patent/CN112204032A/zh active Pending
- 2019-05-31 BR BR112020023946-1A patent/BR112020023946A2/pt not_active Application Discontinuation
- 2019-05-31 WO PCT/KR2019/006553 patent/WO2019231270A1/en not_active Ceased
- 2019-05-31 KR KR1020190064284A patent/KR102344295B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20210198259A1 (en) | 2021-07-01 |
| TW202021969A (zh) | 2020-06-16 |
| BR112020023946A2 (pt) | 2021-02-23 |
| EP3807282A1 (en) | 2021-04-21 |
| CN112204032A (zh) | 2021-01-08 |
| SG11202010985TA (en) | 2020-12-30 |
| CA3098825A1 (en) | 2019-12-05 |
| WO2019231270A1 (en) | 2019-12-05 |
| EP3807282A4 (en) | 2022-03-02 |
| JP2021525738A (ja) | 2021-09-27 |
| KR20190137013A (ko) | 2019-12-10 |
| AU2019279421A1 (en) | 2020-12-03 |
| KR102344295B1 (ko) | 2021-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014003042A (es) | Nuevos derivados heterociclicos y sus usos. | |
| MX2020011955A (es) | Derivados heterociclicos y uso de los mismos. | |
| MX2008011369A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2. | |
| MY195588A (en) | Tyrosine Amide Derivatives As Rho- Kinase Inhibitors | |
| IN2012CH01573A (https=) | ||
| SG155909A1 (en) | Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors | |
| TNSN08131A1 (en) | Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| PH12018502531A1 (en) | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune dieases | |
| SA521430920B1 (ar) | P2x3 مشتقات أمينو كينازولين كمثبطات | |
| TNSN08515A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| RU2018142605A (ru) | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма | |
| TNSN07098A1 (en) | 2,6- substituted -4- monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | |
| CY1112805T1 (el) | Παραγωγα πυραζολο (3,4-b) πυριδινης ως αναστολεις της φωσφοδιεστερασης | |
| JP2016531861A5 (https=) | ||
| EA201490492A1 (ru) | Пиримидиновые ингибиторы pde10 | |
| GEAP202516743A (en) | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| MX2019014597A (es) | Inhibidores de pirazolopirimidina de pde9. | |
| EA202192032A1 (ru) | Соединения n-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} и их терапевтическое применение | |
| WO2022221413A3 (en) | E3 ligase binders and uses thereof | |
| WO2012044561A3 (en) | 2-alkoxy pyrimidine pde10 inhibitors | |
| MX2021000759A (es) | Derivados de triazolquinoxalina adicionalmente sustituidos. | |
| MX2021000762A (es) | Derivados de triazoloquinoxalina sustituida. | |
| WO2012054366A3 (en) | Substituted amino-triazolyl pde10 inhibitors |